Umbiko we-American Cancer Society's (ACS) Cancer Facts & Figures 2022, okhishwe namuhla, ukhombisa ukuthi izinga leminyaka emihlanu lokusinda komdlavuza we-pancreatic linyuke lisuka ku-10 laya ku-11%. Okokugcina izinga lokusinda komdlavuza we-pancreatic likhuphuka ngo-2020 lapho liqala ukufinyelela amadijithi aphindwe kabili.
Nakuba lokhu kwanda ngamaphesenti amahlanu kule minyaka eyishumi edlule kubonisa inqubekelaphambili ebalulekile, umbiko we-Facts & Figures uveza futhi ukuthi abantu baseMelika abalinganiselwa ku-62,210 bazotholakala benomdlavuza we-pancreatic ngo-2022, okuwukukhula cishe ngo-3% kusukela ngonyaka odlule. Ngokombiko, nakuba umdlavuza we-pancreatic njengamanje ungumdlavuza we-10 ovame ukutholakala e-US, uhlala uyimbangela yesithathu ehamba phambili yokufa okuhlobene nomdlavuza. Balinganiselwa ku-49,830 abantu baseMelika okulindeleke ukuthi babulawe yilesi sifo kulo nyaka.
Kusukela yasungulwa ngo-1999, i-Pancreatic Cancer Action Network (PanCAN) isithathe indlela ebanzi yokuhlasela umdlavuza oqine kakhulu emhlabeni kuzo zonke izinhlangothi - okuhlanganisa ucwaningo, imizamo yomtholampilo, izinsizakalo zeziguli kanye nokumela abantu abaphansi - ukuze kwenziwe ngcono imiphumela yesiguli futhi kwandiswe jikelele. ukusinda.
“Sijabule kakhulu ngokubona umfutho wezinga lokusinda leminyaka emihlanu. Ngisho nephesenti elilodwa limelela amakhulu eziguli ezinomdlavuza we-pancreatic ezizoba nesikhathi esengeziwe nabathandekayo bazo, kodwa ngeke sigcine lapho,” kusho uJulie Fleshman, JD, MBA, umongameli kanye ne-CEO ye-PanCAN. “U-11% useyizinga lokusinda eliphansi kunawo wonke awomdlavuza omkhulu, ngakho-ke kusenesidingo esiphuthumayo sokwandisa uxhaso, ucwaningo nokuqwashisa njengoba sisebenzela ukuthuthukisa imiphumela yeziguli.”
Ngokomlando, izinga lokusinda komdlavuza we-pancreatic beliphansi ngoba, ngaphandle kwendlela yokutholwa kusenesikhathi futhi ezikhathini eziningi kunezimpawu ezingacacile, ngokuvamile utholakala sekwephuze kakhulu uma isifo sesisabalele. Kuleli qophelo, ukuhlinzwa akuseyona into engenzeka futhi njengamanje kunezinketho zokwelashwa ezilinganiselwe ngamakhemikhali, okugcizelela isidingo esiphuthumayo sendlela yokutholwa kusenesikhathi komdlavuza wamanyikwe kanye nezindlela ezintsha zokwelashwa ezingcono zeziguli.
Uma sibheka esikhathini esizayo, i-PanCAN izibekele umgomo wokufisa ukubona izinga lokusinda leminyaka emihlanu likhuphuka liye ku-20% ngo-2030.
“Yize lo mgomo ulula, awukaphumi kulokho okungenzeka,” kusho uLynn Matrisian, PhD, MBA, isikhulu sesayensi yePanCAN. “Kunezindlela ezimbili ezibalulekile esithuthukisa ngazo ukusinda. Esinye ukutholwa kusenesikhathi. Sibamba umdlavuza kusenesikhathi, sinikeza abantu ithuba eliningi lokuhlinzwa, amathuba amaningi okuwelapha ngama-chemotherapeutic agents. Enye indlela esithuthukisa ngayo ukusinda ukwenza i-chemotherapy nezinye izindlela zokwelapha zibe ngcono.
Kusukela ngo-2003, i-PanCAN itshale imali engaphezu kwezigidi ezingu-149 zamaRandi ocwaningweni, kanye no-$28 wezigidi ezengeziwe okulindeleke kulo nyaka wezimali. Lokhu kuhlanganisa izibonelelo ezingama-218 zososayensi ezweni lonke kanye nezinhlelo ezinkulu zocwaningo ezifana nePanCAN's Precision PromiseSM Clinical Trial, efuna ukusheshisa ukugunyazwa kwezindlela ezintsha zokwelapha iziguli ezinomdlavuza we-pancreatic kanye ne-PanCAN's Early Detection Initiative, enethemba isu lokuxilonga umdlavuza we-pancreatic kusenesikhathi lapho ukuhlinzwa kusengenzeka, okuholela emiphumeleni engcono yesiguli.
Ukuze isekele zonke iziguli ezinomdlavuza wama-pancreas futhi isheshise inqubekelaphambili, i-PanCAN inikeza ukwesekwa kwesiguli kwamahhala, komuntu siqu ngohlelo lwayo Lwezinkonzo Zesiguli, okuhlanganisa ne-Clinical Trial Finder enikeza ukufinyelela kusizindalwazi sakamuva nesiphelele sokuhlolwa komdlavuza we-pancreatic e-United States.
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- This includes 218 grants for scientists across the country as well as large-scale research initiatives such as PanCAN’s Precision PromiseSM Clinical Trial, which seeks to accelerate the approval of new treatment options for pancreatic cancer patients and PanCAN’s Early Detection Initiative, which hopes to develop a strategy to diagnose pancreatic cancer early when surgery is still possible, leading to better patient outcomes.
- Kusukela yasungulwa ngo-1999, i-Pancreatic Cancer Action Network (PanCAN) isithathe indlela ebanzi yokuhlasela umdlavuza oqine kakhulu emhlabeni kuzo zonke izinhlangothi - okuhlanganisa ucwaningo, imizamo yomtholampilo, izinsizakalo zeziguli kanye nokumela abantu abaphansi - ukuze kwenziwe ngcono imiphumela yesiguli futhi kwandiswe jikelele. ukusinda.
- At this point, surgery is no longer a possibility and there are currently limited chemotherapy treatment options, underscoring the urgent need for an early detection method for pancreatic cancer as well as new and better treatment options for patients.
